FY2025 EPS Estimates for TSE:ONC Increased by HC Wainwright

Oncolytics Biotech Inc. (TSE:ONC) – Investment analysts at HC Wainwright lifted their FY2025 earnings per share estimates for shares of Oncolytics Biotech in a note issued to investors on Monday, November 17th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.35) per share for the year, up from their prior estimate of ($0.39). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q4 2025 earnings at ($0.08) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.35) EPS, FY2027 earnings at ($0.32) EPS, FY2028 earnings at ($0.31) EPS and FY2029 earnings at ($0.05) EPS.

Oncolytics Biotech (TSE:ONC) last announced its quarterly earnings data on Wednesday, November 12th. The company reported C($0.14) earnings per share for the quarter.

Separately, Lake Street Capital upgraded shares of Oncolytics Biotech to a “strong-buy” rating in a research note on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy”.

Oncolytics Biotech Price Performance

Shares of TSE ONC opened at C$14.90 on Wednesday. Oncolytics Biotech has a 52 week low of C$0.44 and a 52 week high of C$2.08. The business’s 50 day moving average price is C$14.90 and its 200 day moving average price is C$7.01. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75. The firm has a market cap of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.